4 papers in the library · 319 citations · publishing 2000-2026
JAMA Psychiatry March 18, 2026 James I. Hudson, Harrison G. Pope 1 citation
Can a guided psychedelic experience with psilocybin successfully treat refractory depression? In other words, setting aside any simple direct biological drug effect, can psychedelic-assisted psychotherapy1 alleviate suffering via what William James would call a mystical experience?2
Biological Psychiatry October 15, 2005 John H. Halpern, Andrea R Sherwood, James I. Hudson et al. 186 citations
Hallucinogens are widely used, both by drug abusers and by peoples of traditional cultures who ingest these substances for religious or healing purposes. However, the long-term residual psychological and cognitive effects of hallucinogens remain poorly understood. We recruited three groups of Navajo Native Americans, age 18-45: 1) 61 Native American Church members who regularly ingested peyote,...
Drug and Alcohol Dependence August 16, 2004 John H. Halpern, Harrison G. Pope, Andrea R Sherwood et al.
A substantial literature suggests that users of illicit 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") display residual cognitive deficits. Most MDMA users, however, use other illicit drugs as well, so it is difficult to be certain that these deficits are due to MDMA, as opposed to other drug use or additional confounding factors. We administered a battery of neuropsychological tests to...
American Journal of Psychiatry July 1, 2000 Robert Klitzman, Harrison G. Pope, James I. Hudson 132 citations
OBJECTIVE: The authors explored the association between abuse of 3,4-methylenedioxymethamphetamine (MDMA, or “Ecstasy”) and high-risk sexual behaviors among gay and bisexual men. METHOD: An anonymous questionnaire was completed by 169 gay and bisexual men at three New York City dance clubs. The questionnaire covered demographic indices, use of MDMA and other drugs, and history of high-risk...